RU2014107743A - Очищенные белки - Google Patents
Очищенные белки Download PDFInfo
- Publication number
- RU2014107743A RU2014107743A RU2014107743/10A RU2014107743A RU2014107743A RU 2014107743 A RU2014107743 A RU 2014107743A RU 2014107743/10 A RU2014107743/10 A RU 2014107743/10A RU 2014107743 A RU2014107743 A RU 2014107743A RU 2014107743 A RU2014107743 A RU 2014107743A
- Authority
- RU
- Russia
- Prior art keywords
- cytokine protein
- chimeric cytokine
- protein
- chimeric
- preparation
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 6
- 102000004127 Cytokines Human genes 0.000 claims abstract 54
- 108090000695 Cytokines Proteins 0.000 claims abstract 54
- 238000002360 preparation method Methods 0.000 claims abstract 32
- 239000000203 mixture Substances 0.000 claims abstract 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000012929 tonicity agent Substances 0.000 claims abstract 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims abstract 3
- 229920001993 poloxamer 188 Polymers 0.000 claims abstract 3
- 229940044519 poloxamer 188 Drugs 0.000 claims abstract 3
- 239000001509 sodium citrate Substances 0.000 claims abstract 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract 3
- 239000000600 sorbitol Substances 0.000 claims abstract 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract 2
- 229930195725 Mannitol Natural products 0.000 claims abstract 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract 2
- 229930006000 Sucrose Natural products 0.000 claims abstract 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract 2
- 235000011187 glycerol Nutrition 0.000 claims abstract 2
- 239000000594 mannitol Substances 0.000 claims abstract 2
- 235000010355 mannitol Nutrition 0.000 claims abstract 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract 2
- 229940068977 polysorbate 20 Drugs 0.000 claims abstract 2
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract 2
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract 2
- 239000001632 sodium acetate Substances 0.000 claims abstract 2
- 235000017281 sodium acetate Nutrition 0.000 claims abstract 2
- 239000011780 sodium chloride Substances 0.000 claims abstract 2
- 239000005720 sucrose Substances 0.000 claims abstract 2
- 239000004094 surface-active agent Substances 0.000 claims abstract 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 23
- 238000005341 cation exchange Methods 0.000 claims 4
- 238000000746 purification Methods 0.000 claims 4
- 238000005349 anion exchange Methods 0.000 claims 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000000919 ceramic Substances 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 239000012465 retentate Substances 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3847—Multimodal interactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513453P | 2011-07-29 | 2011-07-29 | |
| US61/513,453 | 2011-07-29 | ||
| US201261591727P | 2012-01-27 | 2012-01-27 | |
| US61/591,727 | 2012-01-27 | ||
| PCT/US2012/048631 WO2013019652A1 (en) | 2011-07-29 | 2012-07-27 | Purified proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014107743A true RU2014107743A (ru) | 2015-09-10 |
Family
ID=46682907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014107743/10A RU2014107743A (ru) | 2011-07-29 | 2012-07-27 | Очищенные белки |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140341843A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2736524A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014522868A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104066439A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012290379A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014002173A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2843197A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2014107743A (cg-RX-API-DMAC7.html) |
| SG (1) | SG10201606218WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013019652A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230776T1 (hr) | 2010-07-29 | 2023-10-27 | Buzzard Pharmaceuticals AB | Himerni antagonisti receptora il-1 tipa i |
| JP6450364B2 (ja) * | 2013-03-13 | 2019-01-09 | セセン バイオ, インコーポレイテッド | 眼送達のためのキメラサイトカイン製剤 |
| AU2013203043B2 (en) | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| DK3461891T3 (da) * | 2014-01-24 | 2020-08-10 | Am-Pharma Bv | Nedstrømsbehandling af en alkalisk phosphatase |
| WO2015138844A1 (en) * | 2014-03-13 | 2015-09-17 | Eleven Biotherapeutics, Inc. | Methods for production of stable chimeric cytokine protein formulations in blow fill seal containers |
| SG11201702757YA (en) * | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| TW201702380A (zh) * | 2015-02-27 | 2017-01-16 | 再生元醫藥公司 | 宿主細胞蛋白質修飾 |
| CN104710527B (zh) * | 2015-02-28 | 2018-08-24 | 苏州金盟生物技术有限公司 | 一种生物制品的内毒素去除方法 |
| CN115598231B (zh) * | 2016-08-15 | 2025-11-18 | 豪夫迈·罗氏有限公司 | 定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法 |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4770781A (en) * | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US4801686A (en) * | 1986-09-04 | 1989-01-31 | Immunex Corporation | Purification of recombinant interleukin-1 |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| JP2799483B2 (ja) * | 1988-03-09 | 1998-09-17 | 大塚製薬株式会社 | インターロイキン−1β組成物の安定化方法 |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| HK1006856A1 (en) * | 1989-11-29 | 1999-03-19 | Amgen Inc. | Production of recombinant human interleukin-1 inhibitor |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| ATE257389T1 (de) * | 1992-09-17 | 2004-01-15 | Amgen Inc | Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| EP0938501B1 (en) * | 1996-06-07 | 2004-07-28 | AVENTIS BULK S.p.A. | Process for the purification of human interleukin-1 receptor antagonist from recombinant e. coli |
| CA2273852C (en) * | 1996-12-06 | 2009-09-29 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| PL1729810T3 (pl) * | 2004-04-02 | 2019-02-28 | Swedish Orphan Biovitrum Ab (Publ) | Sposoby agregacji IL-1ra |
| US7700318B2 (en) * | 2004-08-25 | 2010-04-20 | Amprotein Corporation | Chimeric polypeptide and use thereof |
| CA2589802A1 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| WO2011063195A2 (en) * | 2009-11-20 | 2011-05-26 | Dr. Reddy's Laboratories Ltd. | Purification of modified cytokines |
| HRP20230776T1 (hr) * | 2010-07-29 | 2023-10-27 | Buzzard Pharmaceuticals AB | Himerni antagonisti receptora il-1 tipa i |
| WO2012103240A2 (en) * | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
-
2012
- 2012-07-27 SG SG10201606218WA patent/SG10201606218WA/en unknown
- 2012-07-27 WO PCT/US2012/048631 patent/WO2013019652A1/en not_active Ceased
- 2012-07-27 EP EP12748087.9A patent/EP2736524A1/en not_active Withdrawn
- 2012-07-27 BR BR112014002173A patent/BR112014002173A2/pt not_active IP Right Cessation
- 2012-07-27 US US14/235,777 patent/US20140341843A1/en not_active Abandoned
- 2012-07-27 RU RU2014107743/10A patent/RU2014107743A/ru not_active Application Discontinuation
- 2012-07-27 CA CA2843197A patent/CA2843197A1/en not_active Abandoned
- 2012-07-27 AU AU2012290379A patent/AU2012290379A1/en not_active Abandoned
- 2012-07-27 JP JP2014523080A patent/JP2014522868A/ja active Pending
- 2012-07-27 CN CN201280046036.2A patent/CN104066439A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012290379A1 (en) | 2014-02-06 |
| EP2736524A1 (en) | 2014-06-04 |
| WO2013019652A1 (en) | 2013-02-07 |
| CA2843197A1 (en) | 2013-02-07 |
| JP2014522868A (ja) | 2014-09-08 |
| CN104066439A (zh) | 2014-09-24 |
| BR112014002173A2 (pt) | 2017-03-01 |
| SG10201606218WA (en) | 2016-09-29 |
| US20140341843A1 (en) | 2014-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Banerjee et al. | Cloning and sequence analysis of the Escherichia coli metH gene encoding cobalamin-dependent methionine synthase and isolation of a tryptic fragment containing the cobalamin-binding domain | |
| US20200017545A1 (en) | Methods and Reagents for Purification of Proteins | |
| JP2025505696A5 (cg-RX-API-DMAC7.html) | ||
| JPH10506263A (ja) | コンドロイチンリアーゼ酵素 | |
| HRP20160490T1 (hr) | Pripravak i oblik koji sadrže rekombinantnu humanu iduronat-2-sulfatazu te postupci njihove pripreme | |
| JP2014522868A5 (cg-RX-API-DMAC7.html) | ||
| KR102528707B1 (ko) | 고순도의 히알루로니다제 정제 방법 | |
| ES2639398T3 (es) | Método para producir proteína de interferón recombinante soluble sin desnaturalización | |
| EP3266797B1 (en) | Trail membrane-penetrating peptide-like mutant mur6, preparation method therefor, and application thereof | |
| JP2016535071A5 (cg-RX-API-DMAC7.html) | ||
| JP2014518508A5 (cg-RX-API-DMAC7.html) | ||
| US11584777B2 (en) | Method for purifying a sulfatase protein | |
| JP2025509722A5 (cg-RX-API-DMAC7.html) | ||
| CN114990109B (zh) | 一种核糖核酸纯化伴侣及其应用 | |
| US20260034159A1 (en) | Methods for producing cyclic dinucleotides | |
| RU2004126196A (ru) | Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения и иммунобиологическое средство на его основе | |
| JP2022554283A5 (cg-RX-API-DMAC7.html) | ||
| CN103864916B (zh) | 人胸腺肽β4三倍体蛋白、编码基因及其分离纯化方法 | |
| CN116253789A (zh) | 一种重组蛋白的纯化方法 | |
| EP0446850A2 (en) | Process for purifying recombinant human beta-interferon | |
| WO2026070787A1 (ja) | 脂質二重膜粒子の製造方法及び溶液組成物 | |
| JPH02111729A (ja) | インターフェロンの活性化法 | |
| JP2021114975A (ja) | 組換えタンパク質及びその製造方法 | |
| JP2009263296A (ja) | 分離性向上剤 | |
| RU2015144135A (ru) | Универсальная противогриппозная вакцина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161026 |